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defined to fit the model to the experimental data in terms of 
growth curve, dose response curves, TCD50 and α/β value. 
 
Results: The experimental data are well described for an O2-
independent response. For this case an α/β of 74.7 ± 5.5 Gy 
was obtained. 
When including the effects of O2, we aimed to reproduce this 
high experimental value starting from smaller intrinsic α/β 
values. Unexpected shifts towards lower doses of the 2-Fx 
curves with respect to the 1-Fx curves were observed. This 
effect could be explained by a strong reoxygenation between 
the 1st and the 2nd Fx. Known reoxygenation mechanisms in 
the model include shrinkage, angiogenesis and the increase 
of available O2 due to the presence of dead cells. The latter 
was found to be the dominant mechanism of the three. When 
switching off these mechanisms, the unexpected shifts were 
still observed. A fourth reoxygenation mechanism, which is 
inherent to the original model, was identified. It implicitly 
arises by assuming that the distributions of cells at specific 
O2 levels remained the same after irradiation. To eliminate 
this effect, the histograms were updated to consider the 
actual O2 levels of the surviving cells. After doing so, the 
unexpected shifts of the curves were no longer observed and 
higher simulated values of α/β were obtained. 
 
Conclusion: This work constitutes the first stage of 
experimental validation with preclinical data of a computer 
model which simulates the radiation response of hypoxic 
tumors. It was confirmed that reoxygenation plays an 
important role in the dose response of tumors. Additionally, 
important information on how to further improve the model 
was gathered.  
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Purpose or Objective: SABR (Stereotactic Ablative 
Radiotherapy) is only possible in a subset of patients with 
small tumors and favourable anatomy as the very high BED 
increases the risk of complications. Lung SABR is often 
delivered to tumors that are more peripheral thus; the ribs 
are structures now exposed to significantly higher doses than 
historically has been the case. The first fifty-two SABR 
(Stereotactic Ablative Radiotherapy) patients treated at our 
centre were monitored for rib fracture and chest pain. In this 
study, we fit the data to the LKB model of normal tissue 
response. 
 
Material and Methods: Fifty-two patients were treated with 
either, 55 Gy in 5# (40 patients), 60 Gy in 8# (6 patients) or 
54 Gy in 3# (6 patients) depending on the size and location of 
the tumor. For each patient a chest wall volume was 
delineated. The chest wall volume encompassed the rib and 
chest wall between the ribs. Data were fitted to the Lyman-
Kutcher-Burman (LKB) model, a model using the normal 
cumulative density function to produce a sigmoidal dose 
response curve. The model consists of three parameters 
TD50, which determines the dose at which 50% of treatments 
will result in a complication, m which governs and slope and 
the volume parameter, n. We assumed α/β = 3 Gy. 
 
Results: Of the 52 patients there were 5 occurrences of rib 
fracture (NTCP = 9.6% -6.4%/+11.4%). Leaving the volume 
parameter free in the fit produced best-fit parameters of n = 
0.01, TD50 = 370 Gy and m = 0.45. Due to the small NTCP it is 
difficult to extrapolate to find TD50. This is shown 
graphically in Figure 1; a small change in the slope will have 
a very large effect on the point at which the NTCP is equal to 
50%. Consequently, the uncertainties were large, n could not 
be constrained although very small values were preferred. At 
95% confidence TD50 > 220 Gy and m>0.2, assuming that rib 
fracture is approximately a serial complication. Figure 1 
shows the correlation between TD50 and m at the best-fit 
value of the volume parameter. 
 
 
Conclusion: We conclude that the rate of rib fracture is 
relatively low (<10%) in SABR patients. NTCP modelling 
suggests that a very low volume parameter is most consistent 
with the data. This is in agreement with what might be 
naively expected. Due to small number of patients and 
events analysed to date it is not possible to constrain 
parameters tightly. This may be helped be re-parameterising 
the curve. We are now studying the effects of low absolute 
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Purpose or Objective: Standard power calculation methods 
for randomized trials do not account for patient-to-patient 
differences in effect of novel radiotherapy (RT) techniques. 
The expected advantage of a new technique can often be 
related to heterogeneous dose metrics in individual patients. 
Here, we investigate if model-based outcome assessment can 
affect sample size requirements for a randomized trial of 
proton versus photon RT for lung cancer with reduction of 
severe radiation-induced lung toxicity (RILT) as primary 
endpoint. 
 
Material and Methods: We estimated the number of patients 
needed to demonstrate an advantage of proton versus photon 
RT in a randomized trial, with α=0.05 and 80% power. We 
simulated outcomes using Weibull survival distributions with 
baseline probability of freedom from RITL at 2 years of 85% 
for patients without clinical risk factors. Heterogeneous gain 
from proton therapy was quantified by change in mean lung 
dose (∆MLD), randomly normally distributed in the proton 
arm with mean 4.2 Gy and s.d. 2 Gy. ∆MLD values were 
translated into hazard ratios (HR) using the QUANTEC dose-
response relationship, adjusted for clinical prognostic factors 
(comorbidity, tumour location, smoking status, age) evenly 
distributed between the trial arms. Simulated follow-up was 
distributed over a time period of 2 years. Monte Carlo 
simulations (3000 per data point) were used to assess trial 
power. Sample size estimates were calculated as follows: 
Standard: Comparison of treatment arms using log-rank 
statistics; and Model-based: Cox proportional hazards 
regression fitted to the change in dosimetric predictor, here 
∆MLD. The consequence of a misspecified dose metric was 
assessed by assuming an underlying true effect metric that 
was correlated to, but not equal to, ∆MLD. 
 
Results: Sample size estimates differed considerably for the 
two approaches; see Table 1. 744 patients were needed to 
show the advantage of proton versus photon RT with standard 
comparison of trial arms, while superiority of protons based 
on a direct fit to the effect metric (∆MLD) required only 549 
patients. The advantage of using the model-based method 
